Equities

Nippon Chemiphar Co Ltd

4539:TYO

Nippon Chemiphar Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,490.00
  • Today's Change-10.00 / -0.67%
  • Shares traded10.30k
  • 1 Year change-8.02%
  • Beta0.6937
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Nippon Chemiphar Co Ltd had net income fall from a gain of 339.00m to a loss of 181.00m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 74.06% to 74.83%.
Gross margin26.07%
Net profit margin-0.81%
Operating margin-0.38%
Return on assets-0.50%
Return on equity-1.37%
Return on investment-0.70%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at Nippon Chemiphar Co Ltd fell by 1.33bn. Cash Flow from Financing totalled 1.45bn or 4.71% of revenues. In addition the company generated 297.00m in cash from operations while cash used for investing totalled 3.14bn.
Cash flow per share312.60
Price/Cash flow per share5.63
Book value per share5,141.74
Tangible book value per share5,087.14
More ▼

Balance sheet in JPYView more

Nippon Chemiphar Co Ltd has a Debt to Total Capital ratio of 50.41%, a lower figure than the previous year's 73.98%.
Current ratio2.27
Quick ratio1.52
Total debt/total equity1.02
Total debt/total capital0.5041
More ▼

Growth rates in JPY

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -153.11%. Additionally, five year annualized dividend per share growth ranks below the industry average relative to its peers.
Div yield(5 year avg)2.34%
Div growth rate (5 year)-12.94%
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
51.51
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.